2013 - ISODP 2013 Congress


Mini-Oral 1 on Donation

8.12 - Influence of interleukin 12B , interleukin 16 and interleukin 18 genes polimorphisms on delayed graft function and rejection episodes in patients after kidney transplantation

Presenter: Anita, Sierocka, Szczecin, Poland
Authors: Anita Sierocka, Jan Pawlus, Zbigniew Ziętek, Karol Tejchman, Maciej Romanowski, Andrzej Pawlik, Jerzy Sieńko, Maciej Żukowski, Kazimierz Ciechanowski, Marek Ostrowski, Tadeusz Sulikowski


Influence of interleukin 12B , interleukin 16 and interleukin 18 genes polimorphisms on delayed graft function and rejection episodes in patients after kidney transplantation

Anita Sierocka1, Jan Pawlus1, Zbigniew Ziętek2, Karol Tejchman1, Maciej Romanowski1, Andrzej Pawlik3, Jerzy Sieńko1, Maciej Żukowski4, Kazimierz Ciechanowski5, Marek Ostrowski1, Tadeusz Sulikowski1

1Department of General Surgery and Transplantation, Pomeranian Medical University, Faculty of Medicine, Szczecin, Poland, 2Chair and Department of Anatomy, Pomeranian Medical University, Faculty of Medicine, Szczecin, Poland, 3Department of Experimental and Clinical Pharmacology, Pomeranian Medical Uniwersity, Faculty of Medicine, Szczecin, Poland, 4Clinic of Anaesthesiology and Intensive Care, Pomeranian Medical University, Faculty of Medicine, Szczecin, Poland, 5Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, Faculty of medicine, Szczecin, Poland

Background:Inflammatory mediators have an important role in kidney graft outcomes. The cytokine and chemokine gene polymorphisms are associated with variable production,activity,expression or ligand-receptor affinity[1]. Genetic variation in the DNA sequence of the interleukin 12B (IL-12B), interleukin 16 (IL-16) and interleukin 18 (IL-18) genes may lead to altered cytokine production and activity. These variations can lead to changes in individual's patient outcome after kidney transplantation. That is know,the polymorphisms of interleukins influence on inflammatory diseases, e.g. diabetes, asthma or periodontopathy. Nevertheless there were only few publications about their role in kidney graft outcome [2,3,4].

Aim:The aim of this study was to evaluate the correlation between IL-12B, IL-16 and IL-18 genes polimorphisms with graft function (delayed graft function-DGF) and rejection episodes-acute(AR), chronic(CR).

Materials and methods:267 (38,6% women, 61,4% men) recipients were included to the study. The polymerase chain reaction was used to determine gene polymorphisms of IL-12B(rs3212227), IL-16(4778889), IL-18(rs1946518,rs187238) in serum. Statistical sihnificance (p<0,05) was analised by logit regression (Pearson Chi2, M-L Chi2, Phi, Kendall's test, Gamma test, Spearman Rank R), ANOVA - Tukey's post-hoc test, Odds Ratio (OR)-Chi2 with Yates correction (CI-95%).

Results:Regression analysis revealed no significance between AR/DGF/CR and IL-12B (p=,176/p=,328/p=,438), IL-16 (p=,231/p=,784/p=,287), IL-18-rs1946518 (p=,582/p=,279/p=,084), IL-18-rs187238 (p=,285/p=,279,p=,303). CR group-AAvsCC genotype (IL-18,rs1946518) OR=2,35 (p=,040).

Conclusion:There was no statistical significance between IL-12B, IL-16 and IL-18 gene polimorphisms and kidney graft outcomes after transplantation. Presence of AA genotype IL-18 (rs1946518) is connected with 2,35 higher risk of CR occurence.

Source of Funding:NCN:2013/B/P01/2011/40


You must be logged in to view recordings

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi